Fresh analysis indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle programs.
Findings released in a leading health publication points out that while obese people often shed a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Individuals purchasing these medications must be informed of the risk of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting mass in about 18 months.
Weighing Therapies
The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers note that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Regain
Doctors suggest the mode of action of the injections accounts for the amplified weight return.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the treatment is often long-term.
This view is supported by drug manufacturers, who say that the results "underscore the long-term character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the medication report a sudden resurgence of appetite.
"I experienced a trigger flipping and I was suddenly starving," recalled a patient.
This challenge is compounded if patients have not established permanent dietary or behavioural modifications during treatment.
Growing Use
Figures indicate that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is more common among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are effective tools for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined lifestyle changes.
